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Background: HIV-negative, CD20-negative de novo diffuse large B-cell lymphoma (DLBCL) patients has rarely been
reported. To elucidate the nature of this entity, we retrospectively reviewed the data of 1,456 consecutive de novo
DLBCL patients who were treated at Sun Yat-Sen University Cancer Center between January 1999 and March 2011.
Methods: The pathologic characteristics of CD20-negative patients, clinical features, response to initial treatment,
and outcomes of 28 patients with available clinical data (n = 21) were reviewed. Then, a matched case-control (1:3)
analysis was performed to compare patients with CD20-negative and -positive DLBCL.
Results: The median age of the 28 CD20-negative DLBCL patients was 48 years, with a male-female ratio of 20:8.
Seventeen of 22 (77.3%) CD20-negative DLBCL cases were of the non-germinal centre B-cell (non-GCB) subtype.
High Ki67 expression (≥80%), an index of cell proliferation, was demonstrated in 17 of 24 (70.8%) cases. Extranodal
involvement (≥ 1 site) was observed in 76.2% of the patients. Following initial therapy, 9 of 21 (42.9%) cases
achieved complete remission, 4 (19%) achieved partial remission, 1 (4.8%) had stable disease, and 7 (33.3%) had
disease progression. The median overall survival was 23 months. The 3-year progression-free survival (PFS) and
overall survival (OS) rates were 30.5% and 35%, respectively. A matched case-control analysis showed that patients
with CD20-negative and -positive DLBCL did not exhibit a statistically significant difference with respect to the main
clinical characteristics (except extranodal involvement), whereas the patients with CD20-positive DLBCL had a better
survival outcome with 3-year PFS (P= 0.008) and OS (P= 0.008) rates of 52% and 74.1%, respectively.
Conclusions: This study suggests that HIV-negative, CD20-negative de novo DLBCL patients have a higher
proportion of non-GCB subtype, a higher proliferation index, more frequent extranodal involvement, a poorer
response, and a poorer prognosis to conventional treatment compared to patients with CD20-positive DLBCL.
Further studies are warranted to investigate new target and optimal therapy of CD20-negative de novo DLBCL.
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Diffuse large B-cell lymphoma (DLBCL) is the most fre-
quent subtype of non-Hodgkin’s lymphoma (NHL) in
Western and Eastern countries, representing 30%-40% of
all non-Hodgkin’s lymphoma cases [1,2]. CD20 antigen is
a membrane-bound protein which plays a role in B-cell* Correspondence: wqjiang@yahoo.com
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any medium, provided the original work is propactivation, differentiation, and cell-cycle progression [3-5].
CD20 is an excellent pan-B-cell immunophenotypic
marker because CD20 is highly expressed on the surface
of 90%-95% of normal and neoplastic B lymphocytes;
CD20 is not expressed on immature B precursors and
plasma cells [6,7]. Recent studies have demonstrated that
CD20-negative DLBCL is frequently restricted to a few
variant subtypes of DLBCL with plasmablastic features
and terminal B-cell differentiation, including plasmablastic
lymphoma (PBL) of the oral mucosa type, PBL with plas-
macytic differentiation, primary effusion lymphoma (PEL),his is an Open Access article distributed under the terms of the Creative Commons
/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
erly cited.
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solid lymphoma/extracavitary PEL/HHV-8 associated
DLBCL, and ALK-positive DLBCL [8-14]. Limited studies
with a large series of cases have focused on the clinical
and pathologic features of HIV-negative, CD20-negative
de novo DLBCL patients [9-14].
To shed light on the nature of the entity, we conducted
a matched case-control analysis to compare the clinico-
pathologic characteristics and clinical outcome of HIV-
negative, CD20-negative DLBCL and -positive DLBCL
patients at a single institution. This is the first matched




We retrospectively reviewed the pathologic data of 1,456
consecutive patients with de novo DLBCL diagnosed by
experienced hematopathologists at Sun Yat-Sen University
Cancer Center between January 1999 and March 2011.
Twenty-eight patients were diagnosed as CD20-negative
DLBCL. Among these 28 patients, 21 patients received
treatment at Sun Yat-Sen University Cancer Center and
had available clinical information and follow-up data.
HIV infection test
All 21 patients with CD20-negative DLBCL were initially
screened for HIV infection status before initial therapy.
Blood samples were collected and tested for antibodies
to HIV-1 and -2 using a chromatographic qualitative
enzyme-linked immunosorbent assay (ELISA) test kit
(Atlas Link Biotech Co., Ltd., USA) according to the
manufacturer’s instruction. If samples were positive by
initial ELISA, the results were further confirmed by
Western blot.
Histologic review
All hematoxylin-eosin (HE) paraffin sections of the 28
patients were retrospectively reviewed by at least two
pathologists at Sun Yat-Sen University Cancer Center to
confirm the pathologic diagnosis of DLBCL according to
the criteria of the 2008 World Health Organization clas-
sification [15].
Immunohistochemical studies
Immunohistochemical (IHC) analysis was performed
using a large pane of monoclonal and polyclonal anti-
bodies detecting CD20 (L26, 1:200), CD79a (1:50), CD45
(LCA,1:20), CD3 (1:200), CD5 (1:100), CD10 (1:50),
BCL-6 (1:10), MUM-1 (1:50), BCL-2 (1:80), Ki-67
(1:100), CD30 (1:20), CD38 (1:10), CD138 (1:50), UCHL-
1 (CD45RO,1:200), κ (1:300), λ (1:400), OCT-2 (1:500),
BOB-1 (1:500), CYCLIN D1 (1:50), ALK (1:10), CD43
(1:320), PAX-5, and Vs38c (P63,1:10) antigens (Dako,Glostrup, Denmark). Sections (4 μm thick) were cut
from each paraffin block, deparaffinized, and incubated
at 121oC in citrate buffer (pH 6.0) for 10 min for antigen
retrieval. A routine immunohistochemistry method was
performed for immunostaining the above antigens, as
described previously [16]. For semi-quantitative evalu-
ation of immunostained sections, we used a cut-off value
of 10% to determine CD20 expression or absence accord-
ing to the following criteria: CD20-negative (immuno-
staining of 0-10% of tumor cells); and CD20-positive
(immunostaining of> 10% of tumor cells). The cut-off
value we used in the present study for other proteins (ex-
cept Ki-67) was 30%, according to the following previously
published criteria: negative expression (immunostaining of
0-30% of tumor cells); and positive expression (immuno-
staining of> 30% of tumor cells) [17]. A Ki-67≥ 80% was
consistent with a high proliferation index of lymphoma
cells. In all cases, the percentage of immunostained tumor
cells was consensually estimated by at least two patholo-
gists on a multi-headed microscope. To make sure the
results were as reliable as possible, loss of CD20 expres-
sion was confirmed by at least two experienced hemato-
pathologists in our center. Furthermore, the samples
without CD20 expression were re-immunostained for
CD20 to confirm the findings. Patients were sub-classified
into germinal centre B-cell-like (GCB) and non-GCB
groups based on the algorithm of Hans et al. [17].
In situ hybridization and fluorescence in situ hybridization
study
In situ hybridization (ISH) analysis for Epstein-Barr virus
(EBV)-encoded small RNAs (EBERs) was performed on
paraffin sections of lymphoma tissues with fluorescein-
conjuated peptide nucleic acid probes (Dako), according
to the manufacturer’s instructions. Fluorescent in situ
hybridization (FISH) analysis was performed to detect
the translocation of chromosomes in select cases.
Matched case-control study design
Patients who did not receive rituximab treatment during
the course of their disease were selected from the
remaining 1,428 CD20-positive patients with de novo
DLBCL diagnosed at Sun Yat-Sen University Cancer
Center between January 1999 and March 2011 to serve
as matched controls of patients with CD20-negative
DLBCL. Three control cases were matched to each study
patient with CD20-negative DLBCL. For the 21 CD20-
negative DLBCL with both pathologic and clinical data,
the matching criteria was as follows: a standard inter-
national prognosis index (IPI) score (age, Eastern Co-
operative Oncology Group PS, lactate dehydrogenase
[LDH] level, Ann Arbor stage, and number of extranodal
sites); gender (male or female); and age (±5 years). All of
the above three factors were fully matched between the
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CD20-neagtive DLBCL cases with only pathologic data,
the matching criteria was as follows: gender (male or
female); and age (the same age). Both factors were
matched between the case and the three controls. If
greater than three controls were matched with a case,
three were picked randomly.
This study was approved by the Institutional Review
Board of the National Cancer Institute, as well as the
Ethics Committee of Sun Yat-Sen University Cancer
Center. The study was conducted in accordance with the
Declaration of Helsinki and the institutional guidelines
of the local Ethics Committee.
Statistical methods
Progression-free survival (PFS) was defined as the inter-
val between the date of diagnosis and the date of first
relapse, progression, death, or last follow-up. Overall sur-
vival (OS) was defined from the day of diagnosis until
the time of death or last follow-up. The survival curve
was constructed by the Kaplan-Meier method, and com-
parisons between groups were made using the log-rank
test. The following clinicopathologic variables associated
with survival in common DLBCL were dichotomized to
facilitate univariate analysis for survival of HIV-negative,
CD20-negative de novo DLBCL patients, which were
compared using the Kaplan-Meier method and log-rank
test: age (>60 years vs. ≤ 60 years), Eastern Cooperative
Oncology Group (ECOG) performance status (PS; >1
vs. ≤ 1), stage (stage I/IIvs. stage III/IV), bulky (≥ 7 cm
vs. < 7 cm), serum LDH (normal vs. elevated), extrano-
dal involvement (≥ 2 vs. < 2), IPI (0-1 vs. 2-3), Ki-67
(≥ 80% vs. <80%), BCL-2 (positive vs. negative), mo-
lecular subtypes (GCB vs. non-GCB), response to initial
therapy (complete remission [CR]/partial remission [PR]
vs. stable disease [SD]/progressive disease [PD]).
The clinicopathologic variables of the two groups were
compared using a χ2 test for categorical variables and the
Mann-Whitney test for continuous variables. A two-
tailed P-value <0.05 was considered to be statistically
significant. The statistical software package, SPSS 16.0




Clinical features and HIV test results
For all 28 cases, the median age was 48 years (range, 11-
83 years) and the male-to-female ratio was 20:8. Twenty-
one cases had complete clinical data and follow-up infor-
mation. The baseline clinical information is summarized
in Tables 1 and 2. All of the 21 cases were HIV-negative
and had no history of other lymphoproliferative disor-
ders, organ/hematopoietic stem cell transplantation, orcongenital immunodeficiencies. Twelve cases (57.1%)
had stage I/II disease, and 9 patients (42.9%) had stage
III/IV disease according to the Ann Arbor staging sys-
tem. B symptoms were present in 8 cases (38.1%). Bulky
disease (mass≥ 7 cm) was observed in 8 cases (38.1%).
The serum lactate dehydrogenase (LDH) level was ele-
vated in 7 cases (33.3%). Sixteen patients (76.2%) had
extranodal involvement (11 cases with 1 site, and 5 cases
with> 1 site). Eleven patients (52.4%) had low Inter-
national Prognostic Index (IPI) scores (0-1 risk factor), 5
patients (23.8%) had low-intermediate IPI scores (2 risk
factors), the IPI score was 3 (3 risk factors) in 5 patients
(23.8%), and there were no patients with high-risk IPI
scores (4-5 risk factors). The bone marrow was involved
in 2 patients (9.5%). The PS was< 2 in 18 patients
(85.7%).
Histologic and immunohistochemical features, and ISH and
FISH studies
We reviewed the pathologic data of 1,456 consecutive
patients with de novo DLBCL diagnosed at Sun Yat-Sen
University Cancer Center between January 1999 and
March 2011. Twenty-eight cases (1.9%) met the criteria
for CD20-negative DLBCL. Based on the IHC results
and microscopic morphologic characteristics, 2 of 28
patients were diagnosed as PBL, 3 patients were diag-
nosed as DLBCL with plasmacytic differentiation, and 5
patients were diagnosed as ALK-positive DLBCL accord-
ing to the WHO criteria. There were no patients diag-
nosed as PEL among the 28 cases. The microscopic
morphologic characteristics of 5 ALK-positive DLBCL
patients and 2 PBL patients were as follows: ALK-positive
DLBCL, the tumor showed a sinusoidal growth pattern
and was composed of monomorphic large immunoblast-
like cells with round pale nuclei containing large central
nuclei and abundant cytoplasm, with multinucleated neo-
plastic giant cells in 3 cases; PBL, the tumor showed a dif-
fuse and cohesive proliferation of cells resembling
immunoblasts and mitotic figures were observed in tumor
cells. For the remaining 21 conventional DLBCL cases,
typical morphology of the lymphoma cells was character-
ized by large lymphoid cells diffusely infiltrated lymph
nodes or other tissues. Most of the cells were centroblasts
and cells with plasmacytic differentiation were noted in
three cases. Centroblasts were medium-to-large lymphoid
cells with oval-to-round, vesicular nuclei containing fine
chromatin. There were two-to-four nuclear membrane-
bound nucleoli. The cytoplasm was usually scanty and
amphophilic-to-basophilic (Figure 1A).
The major immunophenotypic features are summar-
ized in Tables 3 and 4. All 28 patients were negative for
CD20. The immunophenotypes are listed as follows
(+/total): CD45, 26 of 27 (96.3%); CD79a, 23 of 26
(88.5%); BOB-1, 9 of 11 (81.8%); OCT-2, 9 of 12 (75%);






















1 68/M - 1 LN IIB No Normal 1 CHOP× 6+RT, ICE × 4,CR AWD 117
2 33/F - 1 Cervical IA No Normal 0 CHOP× 4, CR AND 117
3 49/F - 1 Maxillary sinus,
LN
IIB No Normal 0 CHOP× 5, DHAP× 4, CR DOD 11
4 11/M - 2 Spinal canal,
Retroperitoneal
IIIB Yes Normal 3 Surgical resection+RT, CAV× 2+
BFM-90× 1, PD
DOD 23
5 37/M - 1 Retroperitoneal,
LN, BM
IVB Yes Elevated 2 CHOP× 2,VAD× 2,MEA× 2, PR AND 90
6 56/M - 1 Stomach,
Retroperitoneal,
IIB No Normal 0 CHOP× 6,ICE × 2,DHAP× 3,
GEMOX× 7,Auto PBSCT, PR
DOD 33
7 54/F - 1 Stomach IIB Yes Normal 0 Gastrectomy, CHOP× 6,ICE × 2,
EPOCH× 1,FC × 1, PD
DOD 13
8 73/M - 1 LN IA No Elevated 2 CHOP× 2, PD DOD 7
9 44/M - 1 LN IIIA No Elevated 2 CHOP× 6,HD-MTX +Ara-C × 1, PD DOD 6
10 41/M - 2 Stomach, LN IIA No Elevated 1 CHOP× 2, PD DOD 3
11 66/M - 1 Stomach, LN IIB Yes Elevated 2 EPOCH×6+RT, CR AND 27
12 22/M - 1 Liver, lung,
LN, hip
IVB No Elevated 3 CHOP× 1,DHAP× 2, IMVP-16 × 4, PD DOD 13
13 55/M - 1 LN IA No Normal 0 Bortezomib+EPOCH×4, RT, CR AND 25
14 19/F - 1 Stomach, LN IIA Yes Normal 0 Gastrectomy, CHOP× 6, CR AND 20
15 67/M - 1 Spleen, LN IIIA No Elevated 3 CHOP× 1, ICE × 4,SD AWD 19
16 47/F - 1 Ileum, liver, LN, IVA Yes Normal 2 Surgical resection, CHOP× 1,
MAID× 2,GEMOX× 4,ESHAP× 2, PD
DOD 12
17 27/M - 1 Mediastinum,
pleural
IIA Yes Normal 0 Surgical resection, CHOP+IT × 6, CR AND 15
18 83/M - 1 Lung, rib, LN IVA No Normal 3 CHOP× 3, GEMOX× 2, CR DOD 7
19 53/M - 1 Stomach, LN IIIA No Normal 1 CHOPE× 6,GIFOX× 2,GND× 2, CR AND 9
20 67/M - 1 LN IA No Normal 1 RT,CHOP× 2,Ara-C+DXM× 1,
Ara-C+Paclitaxel × 1, PR
AWD 9
21 71/M - 2 Kidney, sternum,
vertebral, BM
IVA Yes Normal 3 CHOP× 2, ICE × 2, PR DOD 7
Note: -, negative; +, positive; PS, performance status; LN, lymph node; BM, bone marrow; LDH, lactate dehydrogenase; IPI, International Prognostic Index; RT,
radiotherapy; CAV, cyclophosphamide, doxorubicin, vincristine; VAD, vincristine, doxorubicin, dexamethasone; MEA, mitoxantrone, etoposide, cytarabine; GEMOX,
gemcitabine, oxaliplatin; GIFOX, gemcitabine, ifosfamide, oxaliplatin; GND, gemcitabine, vinorelbine, doxil; DXM, dexamethasone; MAID, mesna, doxorubicin,
ifosfamide, dacarbazine; PBSCT, peripheral blood stem cell transplant; IT, intrathecal; CR, complete remission; PR, partial remission; SD, stable disease; PD,
progressive disease; AWD, alive with disease; AND, alive with no evidence of disease; DOD, died of disease.
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of 15 (13.3%); MUM-1, 16 of 21 (76.2%); BCL-2, 13 of 20
(65%); CD30, 9 of 25 (36%); CD38, 8 of 22 (36.4%);
CD138, 5 of 22 (22.7%); kappa, 5 of 11 (45.5%); lambda,
5 of 10 (50%); ALK, 5 of 24 (20.8%); CD43, 6 of 14
(42.9%); VS38c (P63), 6 of 15 (40%); CYCLIN D1, 0 of
12; CD5, 0 of 23; and CD23, 0 of 11. Of the T cell- or
NK/T cell-associated markers (CD3 and CD56, respect-
ively), 0 of 26 and 0 of 9 were positive in lymphoma
cells, respectively. Interestingly, the T cell-associated
antigen, UCHL-1(CD45RO), was positive in 3 of 23
(13%) cases. According to the Hans algorithm [17], 17 of
22 (77.3%) cases were categorized as non-GCB type,while 5 of 22 (22.7%) cases were categorized as GCB
type. Ki-67 was immunolabelled as a high proliferation
index (≥ 80%) for lymphoma cells in 17 of 24 (70.8%)
cases (Figure 1K).
Only 1 of 21 cases (4.8%) tested for EBV infection had
positive signals in the nuclei of the lymphoma cells in
EBERs ISH. Both IgH-MALT-1/t (14; 18) and API-2-
MALT-1/t (11; 18) were negative in the one case tested
by FISH.
Response and survival analysis
Twenty of 21 CD20-negative de novo DLBCL cases
received cyclophosphamide, doxorubicin, vincristine, and
Table 2 Clinical characteristics of CD20-negative diffuse








Median (range) 51.5(9-83) 53(11-83) 51(9-71) 0.955
≤60 56(66.7%) 14(66.7%) 42(66.7) 1
Sex
Male 64(76.2%) 16(76.2%) 48(76.2%) 1
Female 20(23.8%) 5(23.8%) 15(23.8%)
PS score
0-1 75(89.3%) 18(85.7%) 57(90.5%) 0.839
≥2 9(10.7%) 3(14.3%) 6(9.5%)
Stage
I-II 49(58.3%) 12(57.1%) 37(58.7%) 0.898
III-IV 35(41.7%) 9(42.9%) 26(41.3%)
LDH
Normal 50(59.5%) 14(66.7%) 36(57.1%) 0.441
Elevated 34(40.5%) 7(33.3%) 27(42.9%)
Extranodal
sites
0-1 73(86.9%) 16(76.2%) 57(90.5%) 0.191
≥2 11(13.1%) 5(23.8%) 6(9.5%)
IPI
0-1 44(52.4%) 11(52.4%) 33(52.4%) 1
2-3 40(47.6%) 10(47.6%) 30(47.6%)
Bulky
disease
Yes 20(23.8%) 8(38.1%) 12(19%) 0.076
No 64(76.2%) 13(61.9%) 51(81%)
BM involvement
Yes 2(2.4%) 2(9.5%) 0(0) 0.06
No 82(97.6%) 19(90.5%) 63(100%)
B symptom
Present 23(27.4%) 8(38.1%) 15(23.8%) 0.204
Absent 61(72.6%) 13(61.9%) 48(76.2%)
First-line
chemotherapy
CHOP or CHOP-like 79(94%) 20(95.2%) 59(93.7%) 1
Other regimens 5(6%) 1(4.8%) 4(6.3%)
Radiotherapy
Yes 28(33.3%) 5(23.8%) 23(36.5%) 0.285
No 56(66.7%) 16(76.2%) 40(63.5%)
Surgery
Yes 11(13.1%) 5(23.8%) 6(9.5%) 0.191
No 73(86.9%) 16(76.2%) 57(90.5%)
Table 2 Clinical characteristics of CD20-negative diffuse
large B-cell lymphoma and CD20-positive diffuse large B-
cell lymphoma patients (Continued)
Autologous SCT
Yes 4(4.8%) 1(4.8%) 3(4.8%) 1
No 80(95.2%) 20(95.2%) 60(95.2%)
Follow-up
(months)
Median (range) 41.5(2-121) 13(3-117) 47(2-121)
PS, performance status; LDH, lactate dehydrogenase; IPI, international
prognosis index; BM, bone marrow; SCT, stem cell transplantation.
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therapy as first-line chemotherapy. Five cases received
radiotherapy pre- or post-chemotherapy. Five patients
underwent surgical resection as initial treatment. Only
one patient received autologous stem cell transplantation
(SCT) during the course of the disease. Following initial
therapy, 9 of 21 (42.9%) cases achieved CR, 4 (19%)
achieved PR, 1 (4.8%) had SD, and 7 (33.3%) had PD. By
the time of analysis, 11 patients (38.1%) had died; all of
the deaths were due to lymphoma. The median OS time
was 23 months. The estimated 3-year PFS and OS rates
were 30.5% and 35%, respectively (Table 5 and Figures
2A, B). Based on univariate analysis, 3 variables asso-
ciated with a longer OS included a PS ≤ 1 (P= 0.033),
extranodal involvement< 2 sites (P= 0.027), and a CR/
PR response to initial therapy (P= 0.008); however, age
> 60 years, advanced stage (stage III/IV), IPI score (≥ 2),
bulky disease (≥ 7 cm), elevated LDH, high Ki-67, non-
GCB subtype, and positive BCL-2 were not associated
with inferior survival (all P>0.05).
Matched case-control analysis
Clinical characteristics
As expected from the matching method, the two groups
of patients did not show any statistically significant dif-
ference in the main clinical characteristics (Table 2);
however, extranodal involvement (≥1 site) was more fre-
quent in CD20-negative DLBCL patients (76.2% vs.
44.4%, P= 0.012).
Pathologic characteristics
The main pathologic characteristics of the two groups
are listed in Table 4. Compared with CD20-positive
DLBCL in the control group, the non-GCB subtype was
significantly more frequent in CD20-negative DLBCL
(34.4% vs. 77.3%, P= 0.002). Similarly, the proportion of
CD20-negative DLBCL cases with Ki-67 expression ≥
80% was significantly higher than the CD20-positive
DLBCL control group (70.8% vs. 27.7%, P<0.001). Inter-
estingly, CD30-positive expression was more frequent
in the CD20-negative DLBCL group (36% vs. 10.6%,
P= 0.023). There was no significant difference in the rate
Figure 1 Typical morphology and immunophenotype of CD20-negative diffuse large B-cell lymphoma ranged from A to L. A
(Hematoxylin-Eosin staining): Diffuse proliferation of large tumor cells with large nucleus, prominent nucleoli, abundant cytoplasm, and the
karyokinesis were easy to be observed; B: Tumor cells were positive for CD45 (LCA); C: Tumor cells were negative for CD20; D: Tumor cells were
positive for CD79a; E-F: Tumor cells were negative for CD3, CD5; G: Tumor cells were strong positive for CD30; H-I: Tumor cells were negative for
CD10 and BCL-6; J: Tumor cells were positive for MUM-1; K: Tumor cells had a very high proliferation index with Ki-67 highlighting more than 90%
tumor cells; L: Tumor cells were negative for EBERs ISH.
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the study and control groups. However, ALK-positive
DLBCL was more frequent in the CD20-negative DLBCL
group than the CD20-positive DLBCL group (17.9% vs. 0,
P=0.001). Furthermore, the statistical analysis showed no
significant difference in rates of other specified DLBCL sub-
types (PBL and PEL) and DLBCL with plasmacytic differen-
tiation between the two groups of patients (all P>0.05).Response to first -chemotherapy and survival
There were 95.2% and 93.7% CD20-negative DLBCL and
CD20-positive DLBCL patients received CHOP or CHOP-
like treatment as first-line chemotherapy, respectively. The
CR rate of the control group was significantly higher than
the study group (82.5% vs. 42.9%, P=0.001; Table 5). With a
median follow-up of 47 months (range, 2-121 months), the
estimated 3-year PFS and OS rates of the control group










1 68/M LN + - + - - - - NT + 90 -
2 33/F Cevical + - NT NT NT NT NT NT NT NT NT
3 49/F Maxillary Sinus + -† + NT - NT NT NT NT NT NT
4 11/M Spinal canal + - + - - + - - + 80 -
5 37/M Retroperitoneal + - + - - - NT NT NT 80 -
6 56/M Retroperitoneal + - + - - + - - NT 90 -
7 54/F Stomach + - + - - - - - + 80 -
8 73/M LN + - + - - - - - + 80 +
9 44/M LN + - + - - NT - - + 90 NT
10 41/M Stomach + - + NT - NT NT NT NT NT NT
11 66/M Stomach + - + - - NT - - - 80 -
12 22/M Hip + - + NT - NT NT NT - NT NT
13 55/M LN NT - - - - NT - NT + 70 -
14 19/F Stomach + - + - - + - NT + 90 -
15 67/M LN + - { + - - - - - + 70 -
16 47/F Liver + - + - - + - - + 90 -
17 27/M Pleural + - + - NT + - - + 60 -
18 83/M LN + - + - - + + + + 100 NT
19 53/M Stomach + -} + - - + + NT + 100 -
20 67/M LN + -} + - - + - + + 90 -
21 71/M Sternum + - + - - NT + NT NT 90 -
22 62/F LN + - + - - + + NT + 80 -
23 64/M Maxillary sinus + - NT NT - + - - + 80 NT
24 35/M Lung + - - - - - + NT - 60 -
25 40/F Cevical - - - - - + - - - 30 -
26 18/M LN + - + - - + NT NT NT 30 -
27 24/F Ovarian + - + - - - - - - 70 -
28 27/M Mediastinum + - + - - + - - + 100 -
Note: LN, lymphoma node; -, negative; +, positive; NT, not tested; †, {, }, }: CD20 immunostaining in patient 3, 15, 19 and 20 were performed 2, 3, 4 and 2 times,
respectively. All the results of CD20 immunostaining were negative.
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The 3-year PFS and OS in the CD20-negative DLBCL
group were significantly poorer than the CD20-positive
DLBCL group (P=0.008 and P=0.008, respectively; Table 5
and Figure 2).
Discussion
CD20-negative DLBCL is very rare. The vast majority of
reported cases mainly occur in a few variant subtypes of
DLBCL, including PBL, PEL, and ALK-positive DLBCL
[8-14]; however, data on CD20-negative de novo DLBCL
patients are largely limited and limited to HIV-infected
or other immunocompromised patients [8-14]. With the
aim to improve the understanding of this unusual entity,we retrospectively analyzed HIV-negative patients with
CD20-negative DLBCL from a large cohort (n = 1,456)
and performed a matched case-control analysis to com-
pare the clinicopathologic characteristics between CD20-
negative and -positive DLBCL.
Early studies suggested that CD20 plays an important
role in the control of normal B cell activation and pro-
gression through the cell cycle [3-5]. However, the exact
mechanism by which CD20 functions in B cells and the
role of CD20 in DLBCL remains unclear. Bubien et al.
[18] reported that CD20 functions as a Ca2+ channel in
B cell membranes. Although CD20 plays an essential role
in B lymphocytes, CD20-negative DLBCL cells can still
survive after loss of CD20 expression; the reason for this
Table 4 Main pathological characteristics of CD20-negative
diffuse large B-cell lymphoma and CD20-positive diffuse









GCB 26(48.1%) 5(22.7%) 21(65.6%) 0.002
non-GCB 28(51.9%) 17(77.3%) 11(34.4%)
Ki-67
≥80% 30(42.3%) 17(70.8%) 13(27.7%) <0.001
<80% 41(57.7%) 7(29.2%) 34(72.3%)
BCL-2
Positive 37(54.4%) 13(65%) 24(50%) 0.258
Negative 31(45.6%) 7(35%) 24(50%)
EBERs
Positive 2(6.9%) 1(4.8%) 1(12.5%) 0.483
Negative 27(93.1%) 20(95.2%) 7(87.5%)
CD30
Positive 14(19.4%) 9(36%) 5(10.6%) 0.023
Negative 58(80.6%) 16(64%) 42(89.4%)
ALK
Positive 7(20.6%) 5(20.8%) 2(20%) 1





5(4.5%) 5(17.9%) 0(0) 0.001
PBL 2(1.8%) 2(7.1%) 0(0) 0.061
PEL 0(0) 0(0) 0(0) 1
DLBCL with
PD
4(3.6%) 3(10.7%) 1(1.2%) 0.078
IHC, Immunohistochemical; GCB, germinal centre B-cell; DLBCL, diffuse large B-
cell lymphoma; LBCL, large B-cell lymphoma; PBL, plasmablastic lymphoma;
PEL, primary effusion lymphoma; PD, plasmacytic differentiation.
Table 5 Response to first-line chemotherapy and survival in
patients with CD20-negative diffuse large B-cell lymphoma




DLBCL (n = 63)
P
Response
Assessable, n 21 63
CR 9 (42.9%) 52(82.5%) 0.001
No CR 12(57.1%) 11(17.5%)
Survival








DLBCL, diffuse large B-cell lymphoma; CR, complete remission; PFS,
progression-free survival; OS, overall survival.
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eral ion channels [18], some CD20-independent channels
and/or signal transduction pathways essential for the sur-
vival of CD20-negative DLBCL might exist. Further re-
search is warranted to explore the possible transduction
pathways in CD20-negative DLBCL.
CD20-negative DLBCL most frequently occurs in a few
variant subtypes of DLBCL, including PBL and PEL in
the HIV-infected population [8-11,13,19]. It appears that
immunocompromised patients with these DLBCL sub-
types are prone to loss of CD20; however, conclusions
regarding the relationship between loss of CD20 expres-
sion in DLBCL and HIV infections have been inconsist-
ent [19-21]. In a study by Hoffmann et al. [20], only 2%
of HIV-positive DLBCL patients were negative for CD20.
In contrast, Xicoy et al. [21] reported that 26% of HIV-positive DLBCL patients were negative for CD20, and
there were no CD20-negative DLBCL cases among HIV-
negative patients in their study. For PBL, Castillo et al.
[19] reported that the rate of CD20-negative expression
was higher in HIV-negative patients than HIV-positive
patients (100% vs. 83%). The relative lower incidence of
HIV infection in lymphoma patients in China compared
to Western countries may be as a possible explanation
for all 21 cases with CD20-negative DLBCL being HIV-
negative in this series. Further studies are warranted to
elucidate the precise relationship between loss of CD20
and HIV infection in DLBCL patients.
Pathologically, our results showed that CD20-negative
DLBCL is more closely associated with aggressive patho-
logic parameters than CD20-positive DLBCL, with a
higher proliferation index and a higher proportion of
non-GCB type. In the previous two studies, 18% of cases
with a Ki-67 ≥ 80% and 54% of cases with a Ki-67 ≥ 70%
were reported in CD20-positive DLBCL [22,23]. In
agreement with previous results, 27.7% of CD20-positive
DLBCL patients in the present study had a high expres-
sion of Ki-67; however, in the current study, 70.8% of
CD20-negative DLBCL patients had a high proliferation
index (Ki-67≥ 80%). Furthermore, 77.3% of CD20-negative
DLBCL patients were defined as the non-GCB subtype
according to Hans et al. [17]. In comparison, the rate of
non-GCB subtypes was only 34.4% and 58.4% in our con-
trol group and another Chinese study comprising conven-
tional DLBCL [2], respectively. Interestingly, our study
showed that 36% of CD20-negative DLBCL patients were
CD30-positive. In contrast, CD30 expression occurred in
10.6% cases of our control group and 4%-17% of conven-
tional DLBCL cases in other studies [24-26]. This could
have potential therapeutic implication with the advent of
Figure 2 Progression-free survival (PFS) and overall survival (OS) of patients with CD20-negative diffuse large B-cell lymphoma (DLBCL)
and CD20-positive DLBCL. (A): PFS of patients with CD20-negative DLBCL (n = 21, dotted line) and patients with CD20-positive DLBCL (n = 63,
solid line). (B): OS of patients with CD20-negative DLBCL (n = 21, dotted line) and patients with CD20-positive DLBCL (n = 63, solid line).
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gate with significant clinical efficacy in relapsed/refractory
Hodgkin’s lymphoma and systemic anaplastic large-cell
lymphoma [27-29]. Apart from these findings, there was
no significant difference in the rates of expression of ALK,
BCL-2, and EBERs between CD20-negative and -positive
DLBCL.
Several studies have demonstrated that when treated
with CHOP alone, CD20-positive DLBCL attained a CR
rate of> 60% [30-33]. Similar results were observed in
our CD20-positive DLBCL patients (a CR rate of 82%)
when treated with CHOP or CHOP-like chemotherapy;
however, our study showed that less than one-half
(42.9%) of the CD20-negative DLBCL cases achieved a
CR. In addition, the 3-year OS rate for CD20-negative
DLBCL was only 35%, which was much less than CD20-
positive DLBCL (74.1%) in our control group, and even
the 5-year OS rate of conventional DLBCL (52%) before
the rituximab era [34]. The reasons for the poor re-
sponse and outcome to conventional chemotherapy in
the current CD20-negative DLBCL series remain un-
clear. It is noteworthy that although the CD20-negative
DLBCL included 5 cases with ALK-positive DLBCL, 2
cases with PBL, and 3 cases with DLBCL with plasmacy-
tic differentiation, which are known for poor response
and survival rates [8-14], only 2 cases with ALK-positive
DLBCL died and 6 of the above-mentioned 10 DLBCL
cases were alive at the time of last follow-up (the
remaining 2 patients had no clinical data). We can thusassume that the poor response and clinical outcome of
CD20-negative DLBCL is not entirely due to the inclu-
sion of such specified subtypes. However, a high propor-
tion of non-GCB types, a high proliferation index, and
frequent extranodal involvement in CD20-negative
DLBCL might be an explanation because these factors
are associated with biological aggressiveness in conven-
tional DLBCL [17,22,23]. Rituximab, in combination with
chemotherapy, is the standard regimen for de novo
CD20-positive DLBCL. However, rituximab may have lit-
tle value in the initial therapy of de novo CD20-negative
DLBCL patients. A lack of active targeted therapy for
CD20-negative DLBCL might also contribute to the poor
prognosis. Recent studies have indicated that a higher
level of CD20 expression correlates with improved OS in
B cell lymphoma patients treated with rituximab [35,36].
Furthermore, the study by Johnson et al. [37] demon-
strated that DLBCL with reduced CD20 expression had a
markedly inferior survival when treated with CHOP or
rituximab-CHOP. Further investigations are warranted to
evaluate the CD20-independent survival pathway and to
develop new optimal therapy in CD20-negative DLBCL.
The IPI score is a useful tool in predicting outcome in
typical DLBCL treated with conventional chemotherapy
[34]. However, univariate analysis in our study failed to
demonstrate an association between survival and IPI. In
addition, except for a PS≥ 2, extranodal involvement≥2,
and a SD/PD response to initial therapy, the other clinical
characteristics (increased age, advanced stage, elevated LDH
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Moreover, a recent report showed that an immunohisto-
chemical biomarker, such as BCL-2, can predict OS in con-
ventional DLBCL treated with CHOP [38]. Another study
by Miller et al. [22] demonstrated that DLBCL patients with
a high Ki-67 (≥ 80%) had a significantly worse outcome
compared to those with a low Ki-67 (<80%). Similarly, we
showed that a high Ki-67 (but not positive BCL-2) was
associated with inferior survival in patients with CD20-
positive DLBCL (data not shown). However, Ki-67 and
BCL-2 did not have prognostic value in CD20-negative
DLBCL. One possible reason for this negative result is that
the biological behavior of CD20-negative DLBCL may be
different from that of CD20-positive DLBCL.
Conclusions
In conclusion, our study indicated that CD20-negavtive
DLBCL is strikingly rare. With a higher proportion of
non-GCB types, a higher proliferation index, and more
frequent extranodal involvement compared to CD20-
positive DLBCL, most of the CD20-negative DLBCL
patients had a poor response and prognosis. Optimal
treatment may require special consideration for these
distinctive DLBCL cases. Further studies with a larger
series are warranted to identify the clinicopathologic fea-
tures of HIV-negative, CD20-negative DLBCL patients.
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